{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:08:16Z","timestamp":1773410896963,"version":"3.50.1"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The aim of this study was to compare the efficacy and safety of tigecycline, a newly developed glycylcycline antibiotic, with those of empirical antibiotic regimens which have been reported to possess good efficacy for complicated skin and skin structure infections (cSSSIs), complicated intra-abdominal infections (cIAIs), community-acquired pneumonia (CAP), and other infections caused by methicillin-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA) or vancomycin-resistant\n            <jats:italic>Enterococcus<\/jats:italic>\n            (VRE). A meta-analysis of randomized controlled trials (RCTs) identified in PubMed, the Cochrane Library, and Embase was performed. Eight RCTs involving 4,651 patients were included in the meta-analysis. Compared with therapy with empirical antibiotic regimens, tigecycline monotherapy was associated with similar clinical treatment success rates (for the clinically evaluable [CE] population, odds ratio [OR] = 0.92, 95% confidence interval [CI] = 0.76 to 1.12,\n            <jats:italic>P<\/jats:italic>\n            = 0.42; for the clinical modified intent-to-treat [c-mITT] population, OR = 0.86, 95% CI = 0.74 to 1.01,\n            <jats:italic>P<\/jats:italic>\n            = 0.06) and similar microbiological treatment success rates (for the microbiologically evaluable [ME] population, OR = 0.86, 95% CI = 0.69 to 1.07,\n            <jats:italic>P<\/jats:italic>\n            = 0.19). The incidence of adverse events in the tigecycline group was significantly higher than that in the other therapy groups with a statistical margin (for the modified intent-to-treat [mITT] population, OR = 1.33, 95% CI = 1.17 to 1.52,\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001), especially in the digestive system (mITT population, OR = 2.41, 95% CI = 1.67 to 3.46,\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.00001). No difference regarding all-cause mortality and drug-related mortality between tigecycline and the other regimens was found, although numerically higher mortality was found in the tigecycline group. This meta-analysis provides evidence that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA\/VRE. However, because of the high risk of mortality, AEs, and emergence of resistant isolates, prudence with the clinical use of tigecycline monotherapy in infections is required.\n          <\/jats:p>","DOI":"10.1128\/aac.01402-10","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T06:06:50Z","timestamp":1292911610000},"page":"1162-1172","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":154,"title":["Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease"],"prefix":"10.1128","volume":"55","author":[{"given":"Yun","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, the PLA General Hospital, Beijing 100853, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, the PLA General Hospital, Beijing 100853, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, the PLA General Hospital, Beijing 100853, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, the PLA General Hospital, Beijing 100853, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youning","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases, the PLA General Hospital, Beijing 100853, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/526775"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/431488"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.09.001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.9.2226"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.48443"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.11.4658-4666.2005"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-217"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2007.09.017"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/ja.2009.111"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2009.21.1.58"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.7.1052"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.Supplement-1.28"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.011"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/588557"},{"key":"e_1_3_2_16_2","unstructured":"Drug safety announcement\u2014tigecycline. 2010"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn250"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.Supplement-1.12"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1086\/648720"},{"key":"e_1_3_2_20_2","first-page":"681","volume":"40","year":"2008","unstructured":"Gilson, M., et al. 2008. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand. J. Infect. Dis. 40:681-683.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1201-9712(07)60002-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/599224"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1258\/1355819021927674"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.236"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050487"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2008.056689"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01340-07"},{"key":"e_1_3_2_30_2","first-page":"1081","volume":"38","year":"2006","unstructured":"Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2006. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand. J. Infect. Dis. 38:1081-1084.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-5-88"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2009.06.019"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(09)70005-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.8.1198"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2005.17.Supplement-1.12"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2005.05.003"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H229"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2008.03.023"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47286-0"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(01)00377-8"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0557-8"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-006-0123-1"},{"key":"e_1_3_2_43_2","first-page":"329","volume":"61","year":"2008","unstructured":"Tanaseanu, C., et al. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 61:329-338.","journal-title":"Infect. Dis."},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-9-44"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2008.20.Supplement-1.20"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2010.03122.x"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn249"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.2007.456"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.5144\/0256-4947.51779"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00055705"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01402-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01402-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:19:36Z","timestamp":1645485576000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01402-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1128\/AAC.01402-10"],"URL":"https:\/\/doi.org\/10.1128\/aac.01402-10","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2010-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-12-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}